Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EC approves Menarini and NewAmsterdam’s obicetrapib therapies
Obicetrapib is being developed as a low-dose, oral CETP inhibitor for lowering LDL cholesterol in patients unresponsive to treatments. Credit: PeopleImages / Shutterstock.com.
Obicetrapib is being developed as a low-dose, oral CETP inhibitor for lowering LDL cholesterol in patients unresponsive to treatments. Credit: PeopleImages / Shutterstock.com.